Reduction or Extension of COnduction Time With Ventricular Electromechanical Remodeling (RECOVER)
RECOVER
Prospective Multicenter Observation Study on the Serial Changes in Ventriculo-ventricular Conduction Times According to Cardiac-resynchronization Therapy Response
1 other identifier
observational
100
1 country
6
Brief Summary
This prospective multicenter registry study aims to detect the serial changes in ventriculo-ventricular conduction times according to cardiac-resynchronization therapy response.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jul 2018
Longer than P75 for all trials
6 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 20, 2018
CompletedFirst Submitted
Initial submission to the registry
May 17, 2020
CompletedFirst Posted
Study publicly available on registry
May 21, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 20, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
July 20, 2024
CompletedJune 30, 2021
June 1, 2021
4 years
May 17, 2020
June 29, 2021
Conditions
Outcome Measures
Primary Outcomes (1)
Serial change of ventriculo-ventricular conduction times
Reduction or extension of ventriculo-ventricular conduction times
from enrollment to last follow-up (2 years)
Study Arms (2)
CRT responder
CRT non-responder
Interventions
Ventriculo-ventricular conduction time measurement using device analyzer
Eligibility Criteria
Heart failure patients implanted with multipoint pacing CRT device and quadripolar left ventricular lead from Abbott
You may qualify if:
- meeting the current ESC or ACCF/AHA/HRS Class I or Class IIa indications for cardiac-resynchronization (CRT) implant
You may not qualify if:
- Myocardial infarction, unstable angina within 40 days prior the enrollment
- Recent cardiac revascularization in the 4 weeks prior to the enrollment or planned for the 3 months following
- Cerebrovascular accident (CVA) or transient ischemic attack (TIA) in the 3 months prior to the enrollment
- Primary valvular disease requiring surgical correction
- Pregnant or are planning during the duration of the investigation
- Status 1 candidate for cardiac transplantation or consideration for transplantation over the next 12 months
- Post-cardiac transplantation
- Life expectancy \< 12 months
- Currently participating in any other clinical investigation except for observational registry
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Samsung Medical Centerlead
- Abbott Medical Devicescollaborator
Study Sites (6)
Sejong General Hospital
Bucheon-si, South Korea
Samsung Changwon Medical Center
Changwon, South Korea
Chungnam National University Hospital
Daejeon, South Korea
Eulji University Hospital
Daejeon, South Korea
Seoul National University Bundang Hospital
Seongnam, South Korea
Samsung Medical Center
Seoul, South Korea
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 17, 2020
First Posted
May 21, 2020
Study Start
July 20, 2018
Primary Completion
July 20, 2022
Study Completion
July 20, 2024
Last Updated
June 30, 2021
Record last verified: 2021-06